Sanofi (SNY) is scheduled to report Q2 earnings on July 30, 2026. Analysts estimate EPS of $1.20 and quarterly revenue of $12.54B.
In the most recent quarter (Q1), Sanofi reported EPS of $1.10, beating estimates of $1.06 by 0.04%. Revenue came in at $12.31B, exceeding the estimate of $11.99B by 0.03%.
Sanofi has beaten EPS estimates in 3 consecutive quarters.
Over the last 4 quarters, Sanofi has averaged an EPS surprise of 0.06% and a revenue surprise of 0.02%.
Analyze the earnings history of Sanofi using advanced sorting and filters.
The chart below shows Sanofi's reported EPS compared to analyst estimates over recent quarters.
The chart below shows Sanofi's reported revenue compared to analyst estimates over recent quarters.
Sanofi (SNY) is scheduled to report earnings on July 30, 2026. The last reported earnings were for reported on April 23, 2026 for Q1.
The Actual EPS was $1.10, which beat the estimate of $1.06.
The Actual Revenue was $12.31B, which beat the estimate of $11.99B.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q1 | 2026-04-23 | $1.10 | $1.06 | 3.77 % |
| Q4 | 2026-01-29 | $0.89 | $0.84 | 5.95 % |
| Q3 | 2025-10-24 | $1.70 | $1.60 | 6.31 % |
| Q2 | 2025-07-31 | $0.90 | $0.96 | -6.15 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q1 | 2026-04-23 | $12.31B | $11.99B | 2.64 % |
| Q4 | 2026-01-29 | $13.16B | $13.41B | -1.87 % |
| Q3 | 2025-10-24 | $14.54B | $14.46B | 0.54 % |
| Q2 | 2025-07-31 | $11.33B | $11.53B | -1.72 % |